Finance & markets

Galapagos NV Announces Gamgertamig Preliminary Phase 1b Data and Poster Presentation at 2026 ASH Meeting

Policy desk, National Trade News (2026-11-04): Galapagos NV announced the acceptance of a poster presentation at the 2026 American Society of Hematology Annual Meeting, scheduled for December 12-15,… Primary source: original at Nasdaq (nasdaq.com).

November 4, 2026 7:52 PM GMT · Nasdaq

Galapagos NV announced the acceptance of a poster presentation at the 2026 American Society of Hematology Annual Meeting, scheduled for December 12-15, featuring preliminary data for gamgertamig in relapsed/refractory autoimmune cytopenias. Gamgertamig is an investigational BCMAx

Read at source

Read also

CollPlant Biotechnologies Ltd. Announces Proposed Name Change to OptiPhi Computing

Every stock that moved because of the election

Qualcomm stock drops 6% on weak earnings forecast as memory shortage weighs on smartphone sales